The ability to vaccinate an at-risk civilian population with vaccinia virus is central to preparing for the potential threat of smallpox bioterrorism. However, a critical limitation of this strategy is the recognized complications of vaccinia vaccination, particularly in immunocompromised hosts, pregnant women, and infants. Therapeutic interventions currently available to counter such complications are inadequate and novel strategies are needed. We propose to develop such new therapies that target related, yet functionally distinct, vaccinia proteins. The vaccinia complement-control protein (VCP) and the extracellular enveloped virus (EEV)-specific B5R protein both contain short consensus repeat (SCR) units present in complement regulatory proteins. We have shown that VCP and the B5R proteins are critical for pathogenesis in vivo. VCP inhibits complement activation and helps the virus evade the host complement mediated attack. The B5R protein is essential for efficient viral dissemination. Our hypothesis is that these viral SCR-containing proteins have critical functions in pathogenesis that make them uniquely suited to serve as novel targets for therapeutic strategies directed at complications occurring during vaccinia immunization. Individuals with life-threatening vaccinia virus vaccine complications usually have defective cell-mediated or humoral immunity, but typically have intact innate immune function. A therapeutic inhibitor of VCP's complement control activity would therefore be a novel approach to managing vaccinia vaccine complications because such an inhibitor would allow the host's innate immune system to regain control of the infection.
In Specific Aim number 1, we will utilize phage library display to identify specific inhibitors of VCP that prevent its inhibition of the complement cascade. The B5R protein is one of several EEV-specific proteins. B5R also contains SCRs and, while complement regulatory activity has not been identified, we and others have demonstrated that B5R is critical for EEV formation and viral spread in vivo. In addition, recent reports have shown that B5R is one of the principal targets for EEV neutralizing antibodies. Thus, therapeutic targeting of B5R offers an additional way of controlling vaccinia virus replication and dissemination.
In Specific Aim number 2 we will develop monoclonal antibodies (mAbs) to the B5R protein and identify mAbs that neutralize EEV. We believe that identification of such mAbs (along with a cocktail of humanized mAbs to other EEV-specific proteins) can form the basis for a passive immune neutralization strategy to control vaccinia virus vaccine complications. We anticipate that these proteins will provide novel targets for immunomodulation of vaccinia virus. In addition, because both VCP and BSR are present in variola virus, these new therapies may be effective against smallpox infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI048487-03
Application #
6534302
Study Section
Special Emphasis Panel (ZAI1-PSS-M (S1))
Program Officer
Meegan, James M
Project Start
2000-09-01
Project End
2004-07-31
Budget Start
2002-09-01
Budget End
2003-07-31
Support Year
3
Fiscal Year
2002
Total Cost
$268,453
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Foo, Chwan Hong; Whitbeck, J Charles; Ponce-de-Leon, Manuel et al. (2012) The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry. J Virol 86:5437-51
Foo, Chwan Hong; Lou, Huan; Whitbeck, J Charles et al. (2009) Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans. Virology 385:368-82
Whitbeck, J Charles; Foo, Chwan-Hong; Ponce de Leon, Manuel et al. (2009) Vaccinia virus exhibits cell-type-dependent entry characteristics. Virology 385:383-91
Aldaz-Carroll, Lydia; Xiao, Yuhong; Whitbeck, J Charles et al. (2007) Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J Virol 81:8131-9
Sfyroera, Georgia; Katragadda, Madan; Morikis, Dimitrios et al. (2005) Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol 174:2143-51
Aldaz-Carroll, Lydia; Whitbeck, J Charles; Ponce de Leon, Manuel et al. (2005) Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol 79:6260-71
Mastellos, D; Morikis, D; Strey, C et al. (2004) From atoms to systems: a cross-disciplinary approach to complement-mediated functions. Mol Immunol 41:153-64
Bell, Edward; Shamim, Mohammad; Whitbeck, J Charles et al. (2004) Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325:425-31
Isaacs, Stuart N (2004) Working safely with vaccinia virus: laboratory technique and the role of vaccinia vaccination. Methods Mol Biol 269:1-14
Isaacs, Stuart N; Argyropoulos, Emelia; Sfyroera, Georgia et al. (2003) Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J Virol 77:8256-62

Showing the most recent 10 out of 17 publications